RecruitingPHASE2, PHASE3NCT05543616
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
Studying Severe acute respiratory syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BioNTech SE
- Principal Investigator
- Pfizer CT.gov Call CenterPfizer
- Intervention
- Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose(biological)
- Enrollment
- 4292 target
- Eligibility
- 11 years · All sexes
- Timeline
- 2022 – 2026
Study locations (30)
- UAB Child Health Research Unit (CHRU), Birmingham, Alabama, United States
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- Northwest Arkansas Pediatric Clinic, Fayetteville, Arkansas, United States
- Advanced Research Center Inc., Anaheim, California, United States
- Paradigm Clinical Research Centers, Inc, La Mesa, California, United States
- Hoag Medical Group Foothill Ranch, Lake Forest, California, United States
- Kaiser Permanente, Los Angeles, California, United States
- Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
- Kaiser Permanente Oakland, Oakland, California, United States
- Clinical and Translational Research Unit (CTRU) & Spectrum Biobank, Palo Alto, California, United States
- Center for Clinical Trials, LLC, Paramount, California, United States
- Peninsula Research Associates, Rolling Hills Estates, California, United States
- Kaiser Permanente Sacramento, Sacramento, California, United States
- Paradigm Clinical Research, LLC, San Diego, California, United States
- Kaiser Permanente Santa Clara, Santa Clara, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Pfizer
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05543616 on ClinicalTrials.govOther trials for Severe acute respiratory syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06099795Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2Centre Hospitalier Universitaire de Nīmes
- RECRUITINGPHASE4NCT06585241A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsModernaTX, Inc.
- RECRUITINGNCT06168019Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in IndiaBoston University
- RECRUITINGEARLY PHASE1NCT05656105Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) InfectionUniversity of Alabama at Birmingham
- RECRUITINGNCT05892549COVID-19: Early Detection of Worsening by Voice and Respiratory Pattern CharacteristicsDirection Centrale du Service de Santé des Armées
- RECRUITINGNANCT05566483Physiology of Long COVID-19 and the Impact of Cardiopulmonary Rehabilitation on Quality-of-Life and Functional CapacityUniversity of Colorado, Denver
- ACTIVE NOT RECRUITINGNCT05787964Immunity to Infection in Healthy Participants and Participants With CancerUniversity Hospital Tuebingen
- ACTIVE NOT RECRUITINGNCT05032976Korea Comirnaty Post-marketing SurveillancePfizer